Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial

Endocrine

Volumn 46, Issue 3, 2014, Pages 577-584

  Vilar, Lucio ^a   Fleseriu, Maria ^b   Naves, Luciana Ansaneli ^c   Albuquerque, José Luciano ^d   Gadelha, Patrícia Sampaio ^a   Dos Santos Faria, Manuel ^e   Nascimento, Gilvan Cortês ^e   Montenegro, Renan Magalhães ^f  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^d Hospital Otávio de Freitas HOF   (Brazil)

^e FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^f FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Acromegaly; Octreotide LAR; Treatment withdrawal

Indexed keywords

CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; DELAYED RELEASE FORMULATION; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY (TOPIC); PATIENT HISTORY OF RADIOTHERAPY; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; REMISSION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ACROMEGALY; ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899732125     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0094-9     Document Type: Article

References (34)

1. S. Melmed, F.F. Casanueva, A. Klibanski, M.D. Bronstein, P. Chanson, S.W. Lamberts, C.J. Strasburger, J.A. Wass, A. Giustina, A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294-302 (2013)
2. A. Giustina, M.D. Bronstein, F.F. Casanueva, P. Chanson, E. Ghigo, K.K. Ho, A. Klibanski, S. Lamberts, P. Trainer, S.Melmed, Current management practices for acromegaly: an international survey. Pituitary 14, 125-133 (2011)
3. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Acromegaly Consensus Group, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 119, 3189-3202 (2009)
4. S. Melmed, Acromegaly: pathogenesis and treatment. J. Clin. Invest. 119, 3189-3202 (2009)
5. P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur. J. Endocrinol. 152, 379-387 (2005)
6. C. Schöfl, H. Franz, M. Grussendorf, J. Honegger, C. Jaursch-Hancke, B. Mayr, J. Schopohl, Participants of the German Acromegaly Register, Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur. J. Endocrinol. 168, 39-47 (2012)
7. A. Ben-Shlomo, S. Melmed, Somatostatin agonists for treatment of acromegaly. Mol. Cell. Endocrinol. 286, 192-198 (2008)
8. R.S. Jallad, M.D. Bronstein, The place of medical treatment of acromegaly: current status and perspectives. Expert Opin. Pharmacother. 14, 1001-1015 (2013)
9. P.U. Freda, Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 87, 3013-3018 (2002)
10. M. Fleseriu, Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14, 184-193 (2011)
11. L.F. Grasso, R. Pivonello, A. Colao, Somatostatin analogs as a first-line treatment in acromegaly: When is it appropriate? Curr. Opin. Endocrinol. Diabetes Obes. 19, 288-294 (2012)
12. P.M. Stewart, S.E. Stewart, P.M. Clark, M.C. Sheppard, Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin. Endocrinol. (Oxf.) 50, 295-299 (1999)
13. Y. Lorcy, S. Dejager, P. Chanson, French Octreotide LAR Group, Course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary 3, 193-197 (2000)
14. C.L. Ronchi, E. Rizzo, A.G. Lania, R. Pivonello, S. Grottoli, A. Colao, E. Ghigo, A. Spada, M. Arosio, P. Beck-Peccoz, Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur. J. Endocrinol. 158, 19-25 (2008)
15. C. Ramírez, G. Vargas, B. González, A. Grossman, J. Rábago, E. Sosa, A.L. Espinosa-de-Los-Monteros, M. Mercado, Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: Is it worth trying? Eur. J. Endocrinol. 166, 21-26 (2012)
16. A.M. Pereira, Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Curr. Opin. Endocrinol. Diabetes Obes. 18, 264-268 (2011)
17. O.M. Dekkers, J. Lagro, P. Burman, J.O. Jørgensen, J.A. Romijn, A.M. Pereira, Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95, 43-51 (2010)
18. P. Anagnostis, F. Adamidou, S.A. Polyzos, Z. Efstathiadou, E. Karathanassi, M. Kita, Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15, 25-29 (2012)
19. M. Mercado, F. Borges, H. Bouterfa, T.C. Chang, A. Chervin, A.J. Farrall, A. Patocs, S. Petersenn, J. Podoba, M. Safari, J. Wardlaw, SMS995B2401 Study Group, A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. (Oxf.) 66, 859-868 (2007)
20. A. Barkan, M.D. Bronstein, O.D. Bruno, A. Cob, A.L. Espinosa-de-los- Monteros, M.R. Gadelha, G. Garavito, M. Guitelman, R. Mangupli, M. Mercado, L. Portocarrero, M. Sheppard, Management of acromegaly in Latin America: expert panel recommendations. Pituitary 13, 168-175 (2010)
21. S. Melmed, D. Cook, J. Schopohl, M.I. Goth, K.S. Lam, J. Marek, Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(R) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13, 18-28 (2010)
22. L. Vilar, M.C. Freitas, L.A. Naves, L.A. Casulari, M. Azevedo, R. Montenegro Jr, A.I. Barros, M. Faria, G.C. Nascimento, J.G. Lima, L.H. Nóbrega, T.P. Cruz, A. Mota, A. Ramos, A. Violante, A. Lamounier Filho, M.R. Gadelha, M.A. Czepielewski, A. Glezer, M.D. Bronstein, Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J. Endocrinol. Invest. 31, 436-444 (2008)
23. A.M. Colao, A. Di Sarno, P. Cappabianca, C. Di Somma, R. Pivonello, G. Lombardi, Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349, 2023-2033 (2003)
24. V.Q. Passos, J.J. Souza, N.R. Musolino, M.D. Bronstein, Longterm follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J. Clin. Endocrinol. Metab. 87, 3578-3582 (2002)
25. F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 65, 265-273 (2006)
26. Y.C. Patel, Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. 20, 348-367 (1997)
27. J.S. Bevan, The anti-tumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 90, 1856-1863 (2005)
28. M. Losa, E. Ciccarelli, P. Mortini, R. Barzaghi, D. Gaia, G. Faccani, M. Papotti, F. Mangili, M.R. Terreni, F. Camanni, M. Giovanelli, Effect of octreotide on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 86, 5194-5200 (2011)
29. K. Sharma, Y.C. Patel, C.B. Srikant, Subtype-selective inhibition of wild-type p53 and apoptosis but not cell cycle arrest by human somatostatin receptor 3. Mol. Endocrinol. 10, 1688-1696 (1996)
30. P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, M. Serio, A. Peri, Expression of the antiapoptotic gene seladin-1 and octreotide induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 90, 6156-6161 (2005)
31. E. Hubina, A.M. Nanzer, M.R. Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M.R. Terreni, S. Khalaf, S. Jordan, S. Czirják, Z. Hanzély, G.M. Nagy, M.I. Góth, A.B. Grossman, M. Korbonits, Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 155, 371-379 (2006)
32. E. Ferrante, C. Pellegrini, S. Bondioni, E. Peverelli, M. Locatelli, P. Gelmini, P. Luciani, A. Peri, G. Mantovani, S. Bosari, P. Beck- Peccoz, A. Spada, A. Lania, Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Rel. Cancer. 13, 955-962 (2006)
33. P. Dasqupta, Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol. Ther. 102, 61-85 (2004)
34. N. Garcia, N. de la Torre, J.A. Wass, H.E. Turner, Antiangiogenic effects of somatostatin analogues. Clin. Endocrinol. (Oxf.) 57, 425-441 (2002)